Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dingwei Ye
Observed names:
DING‐WEI YE,
Ding-Wei Ye
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Shanghai Cancer Institute
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Shanghai Cancer Institute
ORCID:
0009-0004-1260-7704
Observed ORCID:
0009-0004-1260-7704
OpenAlex ID:
A5112013563
Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy
2015
·
Gui-Ming Zhang
, Yao Zhu
, et al.
·
Tumor Biology
·
97
Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy
2015
·
Gui-Ming Zhang
, Yao Zhu
, et al.
·
International Journal of Clinical Oncology
·
32
External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer
2017
·
Bo Dai
, Ding-Wei Ye
, et al.
·
Asian Journal of Andrology
·
16
Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study
2020
·
Zhong-Han Zhou
, Feng Liu
, et al.
·
Asian Journal of Andrology
·
13
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
2025
·
Matthew Smith
, Josep Piulats
, et al.
·
The Lancet Oncology
·
11
Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapy
2008
·
Bo Dai
, Yun-Yi Kong
, et al.
·
Asian Journal of Andrology
·
11
Development and validation of a machine learning-based risk model for metastatic disease in nmCRPC patients: a tumor marker prognostic study
2025
·
Xudong Ni
, Ziyun Wang
, et al.
·
International Journal of Surgery
·
10
IL-17RA/CTSK axis mediates H. pylori-induced castration-resistant prostate cancer growth
2024
·
Guowen Lin
, Feng Tian
, et al.
·
Oncogene
·
10
A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).
2025
·
Kim N. Chi
, Rana R. McKay
, et al.
·
Journal of Clinical Oncology
·
8
Extramammary Paget’s diseases in men from the Shanghai area: its association with PSA level increase*
2010
·
GUOHAI SHI
, DING‐WEI YE
, et al.
·
Apmis
·
5
PDF
Anti‐epidermal growth factor receptor monoclonal antibody combined with chemotherapy in penile cancer: A prospective, multicenter, phase 1 study
2025
·
Pei Shu
, Shuang Zhang
, et al.
·
International Journal of Cancer
·
4
Preliminary efficacy and safety of disitamab vedotin (DV) combined with bacillus Calmette-Guérin (BCG) in the treatment of high-risk non-muscle invasive bladder cancer with HER2 expression: A prospective, open label, single-center study.
2025
·
Yijun Shen
, Liangju Peng
, et al.
·
Journal of Clinical Oncology
·
4
PDF
Development and Validation of a Nomogram Including Lymphocyte-to-Monocyte Ratio for Initial Prostate Biopsy: A Double-Center Retrospective Study
2019
·
Zhonghan Zhou
, Feng Liu
, et al.
·
SSRN Electronic Journal
·
2
Abstract 3275: GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial
2020
·
Lin Shen
, Jifang Gong
, et al.
·
Cancer Research
Show more works
View as search
Works count:
14
Citation count:
222
H-index:
8
I10-index:
8
Year
Topic
Type